Antiangiogenic strategies, compounds, and early clinical results in breast cancer

Alessandro Morabito, Roberta Sarmiento, Paola Bonginelli, Giampietro Gasparini

Research output: Contribution to journalArticle

Abstract

Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.

Original languageEnglish
Pages (from-to)91-107
Number of pages17
JournalCritical Reviews in Oncology/Hematology
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Angiogenesis Inhibitors
Breast Neoplasms
Endothelial Growth Factors
Neoplasms
Growth and Development
Vascular Endothelial Growth Factor A
Blood Vessels
Therapeutics
Endothelial Cells
Neoplasm Metastasis
Growth
Clinical Studies

Keywords

  • Angiogenesis
  • Antiangiogenic therapy
  • Breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Antiangiogenic strategies, compounds, and early clinical results in breast cancer. / Morabito, Alessandro; Sarmiento, Roberta; Bonginelli, Paola; Gasparini, Giampietro.

In: Critical Reviews in Oncology/Hematology, Vol. 49, No. 2, 02.2004, p. 91-107.

Research output: Contribution to journalArticle

Morabito, Alessandro ; Sarmiento, Roberta ; Bonginelli, Paola ; Gasparini, Giampietro. / Antiangiogenic strategies, compounds, and early clinical results in breast cancer. In: Critical Reviews in Oncology/Hematology. 2004 ; Vol. 49, No. 2. pp. 91-107.
@article{03f9580d027f45e09098ace1f0674f64,
title = "Antiangiogenic strategies, compounds, and early clinical results in breast cancer",
abstract = "Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.",
keywords = "Angiogenesis, Antiangiogenic therapy, Breast cancer",
author = "Alessandro Morabito and Roberta Sarmiento and Paola Bonginelli and Giampietro Gasparini",
year = "2004",
month = "2",
doi = "10.1016/S1040-8428(03)00168-9",
language = "English",
volume = "49",
pages = "91--107",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Antiangiogenic strategies, compounds, and early clinical results in breast cancer

AU - Morabito, Alessandro

AU - Sarmiento, Roberta

AU - Bonginelli, Paola

AU - Gasparini, Giampietro

PY - 2004/2

Y1 - 2004/2

N2 - Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.

AB - Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastasis. Experimental and clinical data demonstrated that breast cancer is an angiogenesis-dependent disease and that the vascular endothelial growth factor (VEGF) family plays a key role it being a highly expressed and selective endothelial cell growth factor. Preclinical studies have shown that the angiogenic switch occurs early in the multistage process of breast cancer development. Targeting the molecular pathways involved in tumor progression by biologically-designed treatments is a new therapeutic paradigm aimed to reach cancer growth control. A number of possible therapeutic targets for antiangiogenic agents have been identified. Here we discuss the therapeutic approach based on inhibition of angiogenesis in the context of breast cancer with a focus on the early clinical studies on antiangiogenic agents in advanced disease.

KW - Angiogenesis

KW - Antiangiogenic therapy

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0842328584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842328584&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00168-9

DO - 10.1016/S1040-8428(03)00168-9

M3 - Article

C2 - 15012971

AN - SCOPUS:0842328584

VL - 49

SP - 91

EP - 107

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -